Submissions from 2024
VGLL-fusions define a new class of intraparenchymal CNS schwannoma., Simone Schmid, Kanish Mirchia, Anna Tietze, Ilon Liu, Christin Siewert, Jakob Nückles, Jens Schittenhelm, Felix Behling, Matija Snuderl, Christian Hartmann, Sebastian Brandner, Simon M L Paine, Andrey Korshunov, Martin Hasselblatt, Roland Coras, Sridhar Epari, Christine Stadelmann, Sabrina Zechel, Michèle Simon, Yelena Wilson, Francesca Gianno, G Lucas Calixto-Hope, Viktor Zherebitskiy, Vassil B Kaimaktchiev, Lorraina Robinson, Kenneth Aldape, Eelco W Hoving, Bastiaan B J Tops, Ashwyn Augustine Perera, Pauline Göller, Pablo Hernáiz Driever, Pieter Wesseling, Arend Koch, Arie Perry, Felix Sahm, David T W Jones, and David Capper
Exploring the Genomic Landscape of Hepatobiliary Cancers to Establish a Novel Molecular Classification System., Anthony J Scholer, Rebecca Marcus, Mary Garland-Kledzik, Debopriya Ghosh, Miquel Ensenyat-Mendez, Joshua Germany, Juan A Santamaria-Barria, Adam Khader, Javier I Orozco, and Melanie Goldfarb
Palbociclib in Patients With Soft Tissue Sarcoma With, Scott Schuetze, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Funda Meric-Bernstam, Carmen J Calfa, Laura Catherine Farrington, Michael B Livingston, Kristopher Wentzel, Deepti Behl, Yelena Kier, Alissa S Marr, Margaret von Mehren, Joshua Press, Ramya Thota, Gina N Grantham, Abigail Gregory, Dominique C Hinshaw, Susan Halabi, and Richard L Schilsky
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial., Nirav H Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach, William G Wierda, Chaitra S Ujjani, Toby A Eyre, Pier Luigi Zinzani, Alvaro J Alencar, Paolo Ghia, Nicole Lamanna, Marc S Hoffmann, Manish R Patel, Ian Flinn, James N Gerson, Shuo Ma, Catherine C Coombs, Chan Y Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A Barve, Jonathon B Cohen, Wojciech Jurczak, Talha Munir, Meghan C Thompson, Donald E Tsai, Katherine Bao, Nicholas A Cangemi, Jennifer F Kherani, Richard A Walgren, Hongmei Han, Amy S Ruppert, and Jennifer R Brown
Pathologic Features of Miscellaneous Foregut Malignancies., Mark Sharobim, Eduard Matkovic, Michael Schwalbe, and Kristina A Matkowskyj
Trifecta Outcomes After Use of 3-Dimensional Digital Models for Planning of Robotic Prostatectomy: A Secondary Analysis of a Randomized Clinical Trial., Joseph D Shirk, Robert E Reiter, Eric M Wallen, Raymond W Pak, Thomas Ahlering, Ketan K Badani, and James R Porter
Socially vulnerable patients are more likely to fail outpatient management of symptomatic cholelithiasis., Udai S Sibia, John R Klune, Cristina B Feather, Deanna Rider, Douglas Hanes, and Richard Essner
Analysis of 10-year trends in Medicare Physician Fee Schedule payments in surgery., Udai S Sibia, Janelle-Cheri Millen, John R Klune, Anton Bilchik, and Leland J Foshag
Impact of Fall Education to Oncology Staff on Oncology Patient Fall Rates, Danni Sloane
Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis., Kyle E Smoot, Tiffany Gervasi-Follmar, Horia Marginean, Chiayi Chen, and Stanley Cohan
Complications and adverse events in lymphadenectomy of the inguinal area: worldwide expert consensus., René Sotelo, Aref S Sayegh, Luis G Medina, Laura C Perez, Anibal La Riva, Michael B Eppler, José Gaona, Marcos Tobias-Machado, Philippe E Spiess, Curtis A Pettaway, Antonio Carlos Lima Pompeo, Pablo Aloisio Lima Mattos, Timothy G Wilson, Gustavo M Villoldo, Eric Chung, Aldo Samaniego, Antonio Augusto Ornellas, Vladimir Pinheiro, Eder S Brazão, David Subira-Rios, Leandro Koifman, Stênio de Cassio Zequi, Humberto M Pontillo Z, José de Ribamar Rodrigues Calixto, Rafael Campos Silva, B Mark Smithers, Simone Garzon, Oliver Haase, Antonio Sommariva, Robert Fruscio, Francisco Martins, Pedro S de Oliveira, Giovanni Battista Levi Sandri, Marco Clementi, Juan Astigueta, Islam H Metwally, Rasiah Bharathan, Tarun Jindal, Yasuhiro Nakamura, Hisham Abdel Mageed, Sakthiushadevi Jeevarajan, Ramón Rodriguez Lay, Herney Andrés García-Perdomo, Omaira Rodríguez González, Saum Ghodoussipour, Inderbir Gill, and Giovanni E Cacciamani
Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL., Jacob D Soumerai, Jacqueline Claudia Barrientos, Inhye E Ahn, Catherine C Coombs, Douglas E Gladstone, Marc S Hoffmann, Adam S Kittai, Ryan W Jacobs, Andrew Lipsky, Krish Patel, Joanna M Rhodes, Alan P Skarbnik, Meghan C Thompson, Daniel A Ermann, Patrick K Reville, Harsh R Shah, Jennifer R Brown, and Deborah M Stephens
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas., Jacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar, Michaela L Tsai, Thomas A Jandl, Izidore S Lossos, Vaishalee P Kenkre, Farrukh Awan, William Novotny, Jane Huang, Lu Miao, Prabhu Rajagopalan, Richard G Ghalie, and Andrew D Zelenetz
First-in-human study of CDR404, a novel bivalent and bispecific, antibody-derived, T cell engager in MAGE-A4-positive advanced solid cancers, I Spanggaard, Rom Leidner, and See full list of authors in comments
ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study, SA Srour, Brendan Curti, and See full list of authors in comments
Breast Cancer Immunology, Sasha Stanton
Developing immune therapies for prevention in breast cancer, Sasha Stanton
From Receptor Buckets to Receptor Spectrum Guiding Breast Cancer Therapy, Sasha Stanton
HER2 Positive Breast Cancer, Sasha Stanton
Hormone Receptor Positive Breast Cancer, Sasha Stanton
Immunology 101, Sasha Stanton
Moderator and Session Chair: Session 1: Loco-Regional Therapy in Breast Cancer, Sasha Stanton
Advances and challenges in cancer immunoprevention and immune interception., Sasha Stanton, Philip E Castle, Olivera J Finn, Shizuko Sei, and Leisha A Emens
Populations of triple negative and hormone receptor positive HER2 negative breast tumors share immune gene profiles., Sasha Stanton, Frank Schmitz, Wilbert Copeland, Justine DellAringa, Kathryn Newhall, and Mary Disis
Populations of triple negative and hormone receptor positive HER2 negative breast tumors share immune gene profiles., Sasha Stanton, Frank Schmitz, Wilbert Copeland, Justine DellAringa, Kathryn Newhall, and Mary Disis
A Microfluidic, Multi-Antibody Cell Capture Method to Evaluate Tumor Cells in Cerebrospinal Fluid in Patients With Suspected Leptomeningeal Metastases., Nathan T Sweed, Hao-Ching Hsiao, Barbara Blouw, Tony J Pircher, Deanna Fisher, Katrina Rose Naluz, Julie Ann Mayer, Michael C Dugan, Akanksha Sharma, Jose Carrillo, and Santosh Kesari
Development of a Diagnostic Model for Pancreatic Ductal Adenocarcinoma Using Machine Learning and Blood-Based miRNAs., Jason Y Tang, Valentina L Kouznetsova, Santosh Kesari, and Igor F Tsigelny
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors., Matthew H Taylor, Aung Naing, John Powderly, Paul Woodard, Luke Chung, Wen Hong Lin, Hongyu Tian, Nathan Siemers, Hong Xiang, Rong Deng, Kyu Hong, Donna Valencia, Tao Huang, Ying Zhu, X Charlene Liao, Xiao Min Schebye, and Manish R Patel
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors, Jacob Stephen Thomas, Matthew H Taylor, and See full list of authors in comments
Updated results from a phase 1 study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumorsv, J Thomas, Matthew Taylor, and See full list of authors in comments
The Differential Expands: Ataxia from Paraneoplastic Cerebellar Degeneration, Dominic Thomas, MD and Amy Dechet, MD
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors, Sajeve Samuel Thomas and Rom Leidner
Adoptive cell therapy targeting mutations in gastrointestinal cancers, Eric Tran
Cell transfer therapy targeting oncogenic mutations, Eric Tran
More T cell receptors to the RAScue in cancer?, Eric Tran
Past, Present, and Future of Cellular Immunotherapy, Eric Tran
Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature., Angela Trobaugh-Lotrario, Kenichiro Watanabe, Allison F O'Neill, Bozenna Dembowska-Bagińska, Beate Häberle, Andrew Murphy, Eiso Hiyama, Piotr Czauderna, Rebecka L Meyers, Max Langham, and James Feusner
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice., Della Varghese, Giovanna I Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C Faherty, David Harland, and Henry G Kaplan
Management of Neurologic Complications in Patients with Brain and Spine Tumors., Alipi V Bonm and Lynne P Taylor
Interventions to Mitigate Financial Toxicity in Adult Patients with Cancer in the United States: A Scoping Review., Seiichi Villalona, Brenda S Castillo, Carlos Chavez Perez, Alana Ferreira, Isoris Nivar, Juan Cisneros, and Carmen E Guerra
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202., A Vogel, V Sahai, A Hollebecque, G M Vaccaro, D Melisi, R M Al Rajabi, A S Paulson, M J Borad, D Gallinson, A G Murphy, D-Y Oh, E Dotan, D V Catenacci, E Van Cutsem, C F Lihou, H Zhen, M L Veronese, and G K Abou-Alfa
Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAF, Naveed Wagle, Akanksha Sharma, Minhdan Nguyen, Judy D Truong, Tiffany Juarez, and Santosh Kesari
Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020., Michael J Wagner, Vinod Ravi, Stephanie K Schaub, Ed Y Kim, Jeremy Sharib, Harveshp Mogal, Min Park, Michaela Tsai, Daniela Duarte-Bateman, Anthony Tufaro, Elizabeth T Loggers, Lee D Cranmer, Bonny Chau, Michael J Hassett, Juneko Grilley-Olson, and Kelly G Paulson
Corrigendum to "P-REX1 amplification promotes progression of cutaneous melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75]., Jinhua Wang, Hajime Hirose, Guanhua Du, Kelly Chong, Eiji Kiyohara, Isaac P Witz, and Dave S B Hoon
Correction: FOXC1 promotes melanoma by activating MST1R/PI3K/AKT pathway and is associated with poor prognosis in melanoma., Jinhua Wang, Li Li, Shiwei Liu, Ying Zhao, Lin Wang, and Guanhua Du
Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment., Xiaoqiang Wang, Shoubao Ma, Przemyslaw W Twardowski, Clayton Lau, Yin S Chan, Kelly Wong, Sai Xiao, Jinhui Wang, Xiwei Wu, Paul Frankel, Timothy G Wilson, Timothy W Synold, Cary Presant, Tanya Dorff, Jianhua Yu, David Sadava, and Shiuan Chen
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration., Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Baranda, and Antonio Jimeno
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study., Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas, Matthew H Taylor, Kevin B Kim, Meredith McKean, Georgina V Long, Ryan J Sullivan, Mark Faries, Thuy T Tran, C Lance Cowey, Andrew Pecora, Montaser Shaheen, Jennifer Segar, Theresa Medina, Victoria Atkinson, Geoffrey T Gibney, Jason J Luke, Sajeve Thomas, Elizabeth I Buchbinder, Jane A Healy, Mo Huang, Manju Morrissey, Igor Feldman, Vasudha Sehgal, Celine Robert-Tissot, Peijie Hou, Lili Zhu, Michelle Brown, Praveen Aanur, Robert S Meehan, and Tal Zaks
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial., Jeffrey S. Weber, Matthew H Taylor, and See full list of authors in comments
Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy., Yinshen Wee, Junhua Wang, Emily C Wilson, Coulson P Rich, Aaron Rogers, Zongzhong Tong, Evelyn DeGroot, Y N Vashisht Gopal, Michael A Davies, H Atakan Ekiz, Joshua K H Tay, Chris Stubben, Kenneth M Boucher, Juan M Oviedo, Keke C Fairfax, Matthew A Williams, Sheri L Holmen, Roger K Wolff, and Allie H Grossmann
Unveiling Novel Approaches to Expanding Tumor-Reactive T-Cells & Reducing Bystander T-Cells, A Weinberg
Understanding Washington State's Low Uptake of Lung Cancer Screening in Two Steps: A Geospatial Analysis of Patient Travel Time and Health Care Availability of Imaging Sites., Allison C Welch, Jed A Gorden, Stephen J Mooney, Candice L Wilshire, and Steven B Zeliadt
Validation of a Homologous Recombination Deficiency (HRD) Assay for Use in Combination with Comprehensive Genomic Profiling (CGP) Testing, J Welle, Brian Piening, Carlo Bifulco, and See full list of authors in comments
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With, Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Maged F Khalil, Daniel R Carrizosa, Jessica R Bauman, Rom Leidner, Herbert L Duvivier, Siqing Fu, Min Park, Kathleen J Yost, Carmen J Calfa, Alissa S Marr, Ani S Balmanoukian, Deepti Behl, Timothy L Cannon, Lisle Nabell, Steven Francis Powell, Ramya Thota, Dominique C Hinshaw, Abigail Gregory, Gina N Grantham, Susan Halabi, and Richard L Schilsky
Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma., James Wu, Armin Ghobadi, Richard Maziarz, Krish Patel, Hil Hsu, Zihao Liu, Caitlin Sheetz, Peter Kardel, and Christine Fu
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation., Rona Yaeger, Meredith A McKean, Rizwan Haq, J Thaddeus Beck, Matthew H Taylor, Jonathan Eliezer Cohen, Daniel W Bowles, Shirish M Gadgeel, Catalin Mihalcioiu, Kyriakos P Papadopoulos, Eli L Diamond, Keren B Sturtz, Gang Feng, Stefanie K Drescher, Micaela B Reddy, Bhaswati Sengupta, Arnab K Maity, Suzy A Brown, Anurag Singh, Eric N Brown, Brian R Baer, Jim Wong, Tung-Chung Mou, Wen-I Wu, Dean R Kahn, Sunyana Gadal, Neal Rosen, John J Gaudino, Patrice A Lee, Dylan P Hartley, and S Michael Rothenberg
Colorectal Cancer Detection via Metabolites and Machine Learning., Rachel Yang, Igor F Tsigelny, Santosh Kesari, and Valentina L Kouznetsova
Advancing Translational Research, Kim Young
Moderator: SS29: Immunotherapy and Immune Response, Kim Young
Targeting TGBF in Rectal Cancer, Kim Young
Targeting TGFβ in Rectal Cancer, Kim Young
Oncology Social Work Competencies, Opportunities, Roles, and Expertise (CORE): Results from a Role Delineation Study, Bradley Zebrack, Meredith Doherty, Michael Grignon, Ting Guan, Nina Miller, Krista Nelson, Shirley Otis-Green, Makeeta Rayton, Tara Schapmire, and Lori Wiener
Oncologic outcomes following transanal total mesorectal excision: the United States experience., Makda Getachew Zewde, Daniel K Peyser, Allen T Yu, Antoinette Bonaccorso, Erin Moshier, Karim Alavi, Robert Goldstone, John H Marks, Justin A Maykel, Elisabeth C McLemore, Dana Sands, Scott R Steele, Steven D Wexner, Mark Whiteford, and Patricia Sylla
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203., Michelle Y Zhang, Megan Othus, Kerry McMillen, Harry P Erba, Guillermo Garcia-Manero, John M Pagel, Mohamed L Sorror, and Mary-Elizabeth M Percival
A foundation model for joint segmentation, detection and recognition of biomedical objects across nine modalities., Theodore Zhao, Yu Gu, Jianwei Yang, Naoto Usuyama, Ho Hin Lee, Sid Kiblawi, Tristan Naumann, Jianfeng Gao, Angela Crabtree, Jacob Abel, C Moung-Wen, Brian D. Piening, Carlo Bifulco, Mu Wei, Hoifung Poon, and Sheng Wang
Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila., Zhuxian Zhu, Jianguo Huang, Yanling Zhang, Weiwei Hou, Fei Chen, Yin-Yuan Mo, and Ziqiang Zhang
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes., Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, and Emmanuel S Antonarakis
Submissions from 2023
Deep Learning Applications Using H&E Images Improve Clinical Sequencing Workflows, J Abel, Brian Piening, Carlo Bifulco, and See full list of authors in comments
Heterogeneity in the Metastatic Microenvironment: JunB-Expressing Microglia Cells as Potential Drivers of Melanoma Brain Metastasis Progression., Orit Adir, Orit Sagi-Assif, Tsipi Meshel, Shlomit Ben-Menachem, Metsada Pasmanik-Chor, Dave Hoon, Isaac P Witz, and Sivan Izraely
Multi-omics inference of differential breast cancer-related transcriptional regulatory network gene hubs between young Black and White patients., Boris Aguilar, Kawther Abdilleh, and George K Acquaah-Mensah
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With, Eugene R Ahn, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Hussein M Ali-Ahmad, John Chan, Michael L Maitland, Sapna R Patel, Zachary Reese, Ani S Balmanoukian, Charles W Drescher, Rui Li, Apostolia M Tsimberidou, Charles A Leath, Raegan O'Lone, Gina N Grantham, Susan Halabi, and Richard L Schilsky
AAPM BTSC Report 377: Physicist Brachytherapy Training in 2021-A survey of therapeutic medical physics residency program directors., Manik Aima, Samantha J Simiele, Susan L Richardson, and Christopher S Melhus
Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma, Marwah Al-Aloosi, Amanda M Prechtl, Payel Chatterjee, Brady Bernard, Christopher J Kemp, Rachele Rosati, Robert L Diaz, Lauren R Appleyard, Shalini Pereira, Alex Rajewski, Amber McDonald, Eva J Gordon, and Carla Grandori
Liquid biopsies and minimal residual disease in myeloid malignancies., Sabine Allam, Kristina Nasr, Farhan Khalid, Zunairah Shah, Mahammed Ziauddin Khan Suheb, Sana Mulla, Sindhu Vikash, Maroun Bou Zerdan, Faiz Anwer, and Chakra P Chaulagain
Vemurafenib- and Cobimetinib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Metastatic Melanoma., Miriam Al-Saedy, Salsabeal Al-Saedy, and Chad Rieck
Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population., Raed M Alsulaiman, Abdulaziz A Al-Quorain, Fahad A Al-Muhanna, Stanley Piotrowski, Ezzeddin A Kurdi, Chittibabu Vatte, Ahmed A Alquorain, Noorah H Alfaraj, Abdulaziz M Alrezuk, Fred L Robinson, Alexa K Dowdell, Turki A Alamri, Lauren Hamilton, Hetal Lad, Hui Gao, Divya Gandla, Brendan J Keating, Ryan Meng, Brian D. Piening, and Amein K Al-Ali
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)., Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, Marc S Ernstoff, Bernard A Fox, Thomas F Gajewski, Jérôme Galon, Claus Garbe, Brian R Gastman, Jeffrey E Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S Leidner, Roger S Lo, Alexander M Menzies, Olivier Michielin, Poulikos I Poulikakos, Jeffrey S Weber, Corrado Caracò, Iman Osman, Igor Puzanov, and Magdalena Thurin
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022., Paolo A Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, and Igor Puzanov
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial., Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, James Larkin, Georgina V Long, Rachel E Sanborn, Vanna Chiarion-Sileni, Brigitte Dréno, Stéphane Dalle, Dirk Schadendorf, Margaret K Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, and Jean-Jacques Grob
Rare presence of Charcot-Leyden crystals in acute myeloid leukemia., Sujan Badal, Mahnoosh Taheri, Peter Jiang, and Kirstine Oh
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma., Garni Barkhoudarian, Michael Badruddoja, Nicholas Blondin, Sajeel Chowdhary, Charles Cobbs, Julius Paul Duic, John Paul Flores, Ekokobe Fonkem, Edward McClay, Louis Burt Nabors, Michael Salacz, Lynn Taylor, Brian Vaillant, Jaya Gill, and Santosh Kesari
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors, MA Barve, MH Taylor, and See all authors in comments
Early Utilization of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock: The National Cardiogenic Shock Initiative., Mir B Basir, Alejandro Lemor, Sarah Gorgis, Kirit C Patel, Brian C Kolski, Aditya S Bharadwaj, Joshua W Todd, Behnam N Tehrani, Alexander G Truesdell, David M Lasorda, Thomas A Lalonde, Amir Kaki, Theodore L Schrieber, Nainesh C Patel, Shaun R Senter, Joseph L Gelormini, Steven P Marso, Ayaz M Rahman, Robert E Federici, Charles E Wilkins, A Thomas McRae, Ali Nsair, Christopher P Caputo, Matheen A Khuddus, Juan J Chahin, Allison G Dupont, Andrew M Goldsweig, Michael J Lim, Navin K Kapur, David H W Wohns, Yueren Zhou, Michael J Hacala, and William W O'Neill
Health-care expenditures are less for minimally invasive than open colectomy for colon cancer: A US commercial claims database analysis., Amir L Bastawrous, I-Fan Shih, Yanli Li, Marissa Khalil, Biruk Almaz, and Robert K Cleary
Enhancing Anti-tumor Immunity for the Treatment of Head and Neck Cancer, RB Bell
Enhancing Anti-tumor Immunity for the Treatment of Head and Neck Cancer, RB Bell
State of the Art of Head and Neck Cancer Immunotherapy Translational Research, RB Bell
Development and optimization of a broad hyperplex immunofluorescence assay for tumor immune microenvironment characterization, R Ben-Shimol, Carlo Bifulco, Brian Piening, and See full list of authors in comments
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1., B Besse, E Felip, R Garcia Campelo, M Cobo, C Mascaux, A Madroszyk, F Cappuzzo, W Hilgers, G Romano, F Denis, S Viteri, D Debieuvre, D Galetta, E Baldini, M Razaq, G Robinet, M Maio, A Delmonte, B Roch, P Masson, W Schuette, A Zer, J Remon, D Costantini, B Vasseur, R Dziadziuszko, G Giaccone, ATALANTE-1 study group, and Rachel E Sanborn (ATALANTE-1 study group)
A Rare Case of Demodicosis Following Treatment With Oral Fluconazole., Joshua A Bezecny, Emily Bolton, Matthew H Taylor, and Elizabeth G Berry
Empowering Precision Medicine With Genomics, Multi-Modal AI And Real-World Data, C Bifulco
Spatial Biology: Driving Clinical Trials and Diagnostics in a Multiomics AI-Powered Era, C Bifulco
The overview of Spatial Technologies in the use of Immunopathology, C Bifulco
Transforming Patient Care Through Data and AI, C Bifulco
Spatial Biology as a Tool to reveal Mechanisms of Immune Exclusion, Carlo Bifulco
Spatial Biology in a Multiomics AI-Powered Era, Carlo Bifulco
Spatial Omics in Immunotherapy Trials: Unpacking the Challenges, Carlo Bifulco
Implementing CGP plus HRD testing In-house in a Large US Healthcare System, Carlo Bifulco and Brian Piening
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations, JTT Black, MH Taylor, and See all authors in comments
